---
title: "recent"
date: "2024-10-03"
enableToc: true
---

> get back to [[index]]
# 最近編輯的檔案

## 今天

- 2024-10-03 16:33 [[eln_guideline_2024]]
- 2024-10-03 16:33 [[recent]]
- 2024-10-03 10:51 [[acute lymphoblastic leukemia]]
- 2024-10-03 10:51 [[aya all]]
- 2024-10-03 10:41 [[epoch]]
- 2024-10-03 09:02 [[chemotherapy_protocols_in_hematology]]
- 2024-10-03 09:02 [[hematology]]
- 2024-10-03 09:01 [[BENIGN HEMATOLOGY]]
- 2024-10-03 09:01 [[Pocket Oncology]]
- 2024-10-03 09:01 [[Approach to thrombocytopenia]]
- 2024-10-03 09:01 [[thrombocytopenia]]
- 2024-10-03 09:01 [[platelet disorders]]
- 2024-10-03 09:01 [[Primary immune thrombocytopenic purpura (ITP)]]
- 2024-10-03 09:01 [[ITP]]
- 2024-10-03 09:01 [[Treatment of Primary ITP in Adults]]
- 2024-10-03 09:01 [[objectives_of_itp_treatment]]
- 2024-10-03 09:01 [[frontline_rituximab_in_itp]]
- 2024-10-03 09:00 [[Second-line or maintainence therapy for idiopathic thrombocytopenic purpura]]

## 更久以前

- 2024-10-01 17:25 [[TPO-R agonists]]
- 2024-10-01 17:25 [[TPO]]
- 2024-10-01 17:25 [[fostamatinib]]
- 2024-10-01 17:20 [[Eltrombopag]]
- 2024-10-01 17:05 [[itp_course_of_the_disease]]
- 2024-10-01 17:03 [[First-line or upfront therapy for idiopathic thrombocytopenic purpura]]
- 2024-10-01 17:03 [[bleeding_severity_levels_in_itp]]
- 2024-09-28 11:47 [[surveillance_of_nasopharyngeal_carcinoma]]
- 2024-09-28 11:47 [[nasopharyngeal_carcinoma]]
- 2024-09-28 11:47 [[challenges_in_immunotherapy_for_npc]]
- 2024-09-28 11:08 [[staging_of_nasopharyngeal_carcinoma]]
- 2024-09-28 10:37 [[pathology_of_nasopharyngeal_carcinoma]]
- 2024-09-28 10:35 [[diagnosis_workup_of_nasopharyngeal_carcinoma]]
- 2024-09-28 10:35 [[molecular_pathogenesis_of_nasopharyngeal_carcinoma]]
- 2024-09-28 10:35 [[epidemiology_risk_factors_of_nasopharyngeal_carcinoma]]
- 2024-09-28 10:34 [[HEAD AND NECK MALIGNANCIES]]
- 2024-09-28 10:34 [[head_and_neck_squamous_cell_cancer]]
- 2024-09-28 10:15 [[palliative_intent-of-hnscc]]
- 2024-09-28 10:15 [[checkmate_141]]
- 2024-09-28 10:15 [[keynote-040]]
- 2024-09-28 10:15 [[biology_is_king,_selection_is_queen]]
- 2024-09-28 10:00 [[tpextreme]]
- 2024-09-28 10:00 [[keynote-689]]
- 2024-09-28 10:00 [[extreme]]
- 2024-09-28 10:00 [[keynote-048]]
- 2024-09-28 09:49 [[treatment–curative-hnscc]]
- 2024-09-28 09:32 [[role_of_induction_chemotherapy-of-hnscc]]
- 2024-09-28 09:27 [[rtog_91-11]]
- 2024-09-28 09:23 [[tax_323]]
- 2024-09-28 09:19 [[role_of_chemoradiation-hnscc]]
- 2024-09-28 09:18 [[rtog_0522]]
- 2024-09-28 09:14 [[oncology]]
- 2024-09-28 00:56 [[viral_and_non-viral_vectors_for_gene_therapy_and_gene_editing]]
- 2024-09-27 16:57 [[gene_and_cell_therapy_e-school_esmo]]
- 2024-09-27 16:57 [[gene_therapy]]
- 2024-09-27 16:55 [[tp53_sequencing_in_mantle_cell_lymphoma]]
- 2024-09-25 16:48 [[workup_of_mantle_cell_lymphoma]]
- 2024-09-25 16:47 [[nccn_flowchart_of_mantle_cell_lymphoma]]
- 2024-09-25 16:47 [[mantle cell lymphoma]]
- 2024-09-25 16:47 [[MCL]]
- 2024-09-25 16:47 [[MCL 2]]
- 2024-09-25 16:46 [[lyma_regimen]]
- 2024-09-25 16:46 [[triangle_regimen]]
- 2024-09-25 16:39 [[lymphoma 2]]
- 2024-09-25 16:39 [[lymphoma and CLL]]
- 2024-09-25 16:39 [[lymphoma]]